Alpha Cognition Inc.

Alpha Cognition Inc.

NNASDAQ:ACOG
7.83
USD
-0.47
(-5.66%)
-1.36EPS
197.87MMarket Cap
Apr 06Next Earn
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
0.58
0.93
Basic EPS, GAAP
-2.79
-9.16
-4.46
-3.84
-2.04
-1.17
-1.37
Free Cash Flow per Basic Share
-2.63
-4.66
-3.4
-2.45
-1.07
-1.17
-1.42
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
3.34
-0.49
-0.99
2.44
2.88
2.24
Tangible Book Value per Share
-0.34
3.08
-0.71
-1.11
2.41
2.86
1.96
Basic Weighted Avg Shares
2
2
3
4
7
18
22
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
10
20
Operating Margin (%)
- -
- -
- -
- -
- -
-220.93
-149.57
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-6
-20
-12
-14
-15
-21
-30
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-202.24
-147.25
Working Capital
4
10
-2
-1
47
70
49
LT Debt
3
- -
- -
- -
- -
- -
- -
Total Equity
- -
9
-1
-5
39
63
49
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-432.15
- -
- -
- -
-40.68
-71.46

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
120
157
198

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
69
58
57
Cash, Cash Equivalents & STI
54
41
38
Accounts Receivable, Net
4
5
7
Inventories
6
6
6
Total Current Liabilities
5
6
8
Payables & Accruals
5
6
8
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
11,115.44%
59.94%
Free Cash Flow
- -
44.96%
165.65%
Net Income, GAAP
- -
52.14%
39.77%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
3
2
3
3
10
2026
4
6
8
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.87
-0.35
-0.31
-0.51
-2.04
2025
-0.11
-0.82
0.03
-0.32
-1.17
2026
-0.3
-0.4
-0.35
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Michael E. McFadden
Full Time Employees
71
Sector
Finance
Industry
Financial conglomerates
Address
1452 Hughes Street Grapevine TX United States 76051
IPO Date
Nov 12, 2024
Business
Alpha Cognition Inc. (Nasdaq: ACOG) is a commercial-stage biopharmaceutical company that develops and commercializes treatments for neurodegenerative diseases, including Alzheimer's disease and cognitive impairment associated with mild traumatic brain injury (mTBI), primarily in the United States and Canada. The company offers ZUNVEYL (benzgalantamine), an FDA-approved oral tablet prodrug of galantamine indicated for mild-to-moderate Alzheimer's disease that features improved gastrointestinal tolerability and reduced side effects such as nausea; its development pipeline includes ZUNVEYL in combination with memantine for moderate-to-severe Alzheimer's disease, ALPHA-1062 sublingual and intranasal formulations targeting acute pancreatitis and mTBI, respectively, and preclinical assets ALPHA-0602 (progranulin), ALPHA-0702, and ALPHA-0802 for neurodegenerative conditions including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy, some of which are available for out-licensing. Founded in 2000 and headquartered at 750 West Pender Street, Suite 1200, Vancouver, British Columbia V6C 2T8, Canada, Alpha Cognition targets long-term care facilities, neurology clinics, and institutional pharmacies serving patients with limited treatment options in these high-unmet-need areas. Recent developments include the commercial launch of ZUNVEYL in March 2025 generating approximately $2.8 million in revenue through the second quarter of commercialization; a $44 million exclusive licensing agreement in January 2025 with China Medical System Holdings for ZUNVEYL development and commercialization in China, with the partner's New Drug Application accepted by Chinese regulators in July 2025; a $35 million oversubscribed public offering priced in September 2025; appointment of Robert Wills to the board of directors in April 2025; positive preclinical data announced in July 2025 for ALPHA-1062 in a military-relevant model of repetitive mTBI; FDA approval of ZUNVEYL in July 2024 following New Drug Application submission in September 2023; expansions of commercial, medical, and leadership teams in early 2025 to support launch activities; and a notice of allowance for a composition-of-matter patent for ZUNVEYL in October 2024.

Company News

  • Wall Street Analysts Predict an 119.28% Upside in Alpha Cognition Inc. (ACOG): Here's What You Should Know

  • Alpha Cognition Announces Publication of U.S. Patent Application for Benzgalantamine for Treating Persistent Post-Concussion Symptoms

  • Alpha Cognition Inc. (ACOG) Q3 2026 Earnings Call Transcript

  • Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Beats Revenue Estimates

  • What Alpha Cognition (ACOG) Said on Its Q3 Earnings Call

  • Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational Update

  • Alpha Cognition Strengthens Its Board of Directors with Appointment of Caren Deardorf

  • Alpha Cognition to Participate in Upcoming Investor Events

  • Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update

  • Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL®

  • Alpha Cognition Inc. (NASDAQ:ACOG) Receives Average Recommendation of “Buy” from Brokerages

  • Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress

  • Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care

  • Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI)

  • Analysts Set Alpha Cognition Inc. (NASDAQ:ACOG) Target Price at $18.00

  • Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26

  • Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript